L.G. Buchynska, N.M. Glushchenko, N.P. Iurchenko

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine


Summary. Aim: to evaluate the expression pattern of genes associated with ESR1 in the progression of endometrial and breast cancer. Object and methods: protein-protein interactions associated with ESR1 in the progression endometrial (EC) and breast cancer (BRCA) were evaluated based on the STRING v. 12.0 database. Using the interactive databases GEPIA2 and UALCAN, the expression of genes associated with ESR1 in EC and BRCA at the mRNA and protein levels, respectively, was investigated. Results: genes (score > 0.9) associated with ESR1 in both EC and BRCA tumor cells were identified (SRC, CCND1, TP53, PGR, FN1, HIF1A, AKT1). It was established that low values of mRNA expression of CCND1, PGR and high SRC, FN1 in EC and BRCA are associated with an unfavorable prognosis of the course of these oncopathologies. It is shown that lower 5-year survival for patients with EC is observed with a lower expression of TP53, than for patients with BRCA with a higher expression of this indicator. Conclusions: on the basis of prognostic modeling, the interactions of the studied genes associated with ESR1 were determined. Their expression at the levels of proteins and mRNA in EC and BRCA was evaluated, which is associated with the progression of these forms of cancer. Such bioinformatic analysis is the theoretical basis for further validation of a panel of potential biomarkers as informative prognostic indicators associated with the features of oncogenesis of endometrial and mammary gland tissues.

Key words: endometrial cancer, breast cancer, ESR1, bioinformatics databases, gene expression at the mRNA and protein levels.



  1. Miki Y. New insights into breast and endometrial cancers. Cancers (Basel) 2020; 12 (9): 2595. doi: 10.3390/cancers12092595.
  2. Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm Cancer 2019; 10 (2–3): 51–63. doi: 10.1007/s12672-019-0358-9.
  3. Englert-Golon M, Andrusiewicz M, Żbikowska A, et al. Altered expression of ESR1, ESR2, PELP1 and c-SRC genes is associated with ovarian cancer manifestation. Int J Mol Sci 2021; 22 (12): doi: 10.3390/ijms22126216.
  4. Chen J, Cai Y, Xu R, et al. Identification of four hub genes as promising biomarkers to evaluate the prognosis of ovarian cancer in silico. Cancer Cell Int 2020; 20: 270. doi: 10.1186/s12935-020-01361-1.
  5. Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, et al. In silico approach for validating and unveiling new applications for prognostic biomarkers of endometrial cancer. Cancers (Basel) 2021; 13 (20): doi: 10.3390/cancers13205052.
  6. Kim J. In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers. World J Surg Oncol 2021; 19: 188. doi: 10.1186/s12957-021-02301-7.
  7. Shao C, Wang R, Kong D, et al. Identification of potential core genes in gastric cancer using bioinformatics analysis. J Gastrointest Oncol 2021; 12 (5): 2109– doi: 10.21037/jgo-21-628.
  8. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res 2021; 49: D605–D612. doi: 10.1093/nar/gkaa1074.
  9. Persson E, Castresana-Aguirre M, Buzzao D, et al. FunCoup 5: functional association networks in all domains of life, supporting directed links and tissue-specificity. J Mol Biol 2021; 433 (11): doi: 10.1016/j.jmb.2021.166835.
  10. Kim CY, Baek S, Cha J, et al. HumanNet v3: an improved database of human gene networks for disease research. Nucleic Acids Res 2022; 50: D632–D639. doi: 10.1093/nar/gkab1048.
  11. Kamburov A, Herwig R. ConsensusPathDB 2022: molecular interactions update as a resource for network biology. Nucleic Acids Res 2022; 50: D587–D595. doi: 10.1093/nar/gkab1128.
  12. Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res 2018; 46 (W1): W60–W64. doi: 10.1093/nar/gky311.
  13. Greene CS, Krishnan A, Wong AK, et al. Understanding multicellular function and disease with human tissue-specific networks. Nat Genet 2015; 47 (6): 569– doi: 10.1038/ng.3259.
  14. Kotlyar M, Pastrello C, Ahmed Z, et al. IID 2021: towards context-specific protein interaction analyses by increased coverage, enhanced annotation and enrichment analysis. Nucleic Acids Res 2022; 50 (D1): D640– doi: 10.1093/nar/gkab1034.
  15. Wong AK, Krishnan A, Troyanskaya OG. GIANT 2.0: genome-scale integrated analysis of gene networks in tissues. Nucleic Acids Res. 2018; 46 (W1): W65–W70. doi: 10.1093/nar/gky408.
  16. Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The emerging role of the microenvironment in endometrial cancer. Cancers (Basel) 2018; 10 (11): 408. doi: 10.3390/cancers10110408.
  17. Zarrilli G, Businello G, Dieci MV, et al. The tumor microenvironment of primitive and metastatic breast cancer: implications for novel therapeutic strategies. Int J Mol Sci 2020; 21 (21): 8102. doi: 10.3390/ijms21218102.
  18. Kunc M, Popęda M, Biernat W, Senkus E. Lost but not least-novel insights into progesterone receptor loss in estrogen receptor-positive breast cancer. Cancers (Basel) 2021; 13 (19): doi: 10.3390/cancers13194755.
  19. Vella V, De Francesco EM, Lappano R, et al. Microenvironmental determinants of breast cancer metastasis: focus on the crucial interplay between estrogen and insulin/insulin-like growth factor signaling. Front Cell Dev Biol 2020; 8: doi: 10.3389/fcell.2020.608412.
  20. Khatpe AS, Adebayo AK, Herodotou CA, et al. Nexus between PI3K/AKT and estrogen receptor signaling in breast cancer. Cancers (Basel) 2021; 13 (3): 369. doi: 10.3390/cancers13030369.
  21. Manavathi B, Samanthapudi VS, Gajulapalli VN. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front Cell Dev Biol 2014; 2: 34. doi: 3389/fcell.2014.00034.
  22. Yu K, Huang ZY, Xu XL, et al. Estrogen receptor function: impact on the human endometrium. Front Endocrinol (Lausanne) 2022; 13: doi: 10.3389/fendo.2022.827724.
  23. Hou X, Zhao M, Wang T, Zhang G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol Rep 2014; 31: 1175–82. doi: 10.3892/or.2013.2944.
  24. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013; 34 (1): 130–62. doi: 10.1210/er.2012-1043.
  25. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15 (6): 593–602. doi: 10.1111/j.1524-4741.2009.00822.x.
  26. Backes FJ, Walker CJ, Goodfellow PJ, et al. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol 2016; 141 (2): 312–7. doi: 10.1016/j.ygyno.2016.03.006.
  27. Li N, Jiang P, Huang Y, et al. Estrogen receptor- and progesterone receptor-positive thresholds in predicting the recurrence of early low-risk endometrial cancer. Clin Med Insights Oncol 2022; 16: 11795549221103200. doi: 10.1177/11795549221103200.
  28. Jeffreys SA, Becker TM, Khan S, et al. Prognostic and predictive value of CCND1/cyclin D1 amplification in breast cancer with a focus on postmenopausal patients: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13: 895729. doi: 10.3389/fendo.2022.895729.
  29. Ortiz AB, Garcia D, Vicente Y, et al. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS One 2017; 12 (11): e0188068. doi: 10.1371/journal.pone.0188068.
  30. Ramos-García P, González-Moles MÁ, Ayén Á, et al. Predictive value of CCND1/cyclin D1 alterations in the malignant transformation of potentially malignant head and neck disorders: Systematic review and meta-analysis. Head Neck 2019; 41 (9): 3395–407. doi: 10.1002/hed.25834.
  31. Iurchenko NP, Glushchenko NM, Buchynska LG. Assessment of DNA status and peculiarities of expression of cyclins D1, E and transcription factor E2F1 in cells of epithelial endometrial tumors. Oncology 2019; 21 (3): 230–7. doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.7783 (in Ukrainian).
  32. Mohanty A, Sandoval N, Das M, et al. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget 2016; 7 (45): 73558–72. doi: 10.18632/oncotarget.12434.
  33. Xie M, Zhao F, Zou X, et al. The association between CCND1 G870A polymorphism and colorectal cancer risk: a meta-analysis. Medicine (Baltimore) 2017; 96 (42): e doi: 10.1097/MD.0000000000008269.
  34. Siraj AK, Parvathareddy SK, Annaiyappanaidu P, et al. High expression of cyclin D1 is an independent marker for favorable prognosis in middle eastern breast cancer. Onco Targets Ther 2021; 14: 3309–18. doi: 10.2147/OTT.S309091.
  35. Luo J, Zou H, Guo Y, et al. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res 2022; 24 (1): 99. doi: 10.1186/s13058-022-01596-y.
  36. Elsberger B. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer. Crit Rev Oncol Hematol 2014; 89: 343–51. doi: 10.1016/j.critrevonc.2013.12.009.
  37. Hu Y, Wu A-Y, Xu C, et al. MicroRNA-449a inhibits tumor metastasis through AKT/ERK1/2 inactivation by targeting steroid receptor coactivator (SRC) in endometrial cancer. J Cancer 2019; 10 (2): 547–55. doi: 10.7150/jca.27748.
  38. Rasti M, Arabsolghar R, Khatooni Z, Mostafavi-Pour Z. P53 binds to estrogen receptor 1 promoter in human breast cancer cells. Pathology & Oncology Research 2012; 18 (2): 169–75. doi: 10.1007/s12253-011-9423-6.
  39. Berger C, Qian Y, Chen X. The p53-estrogen receptor loop in cancer. Curr Mol Med 2013; 13: 1229–40. doi: 10.2174/15665240113139990065.
  40. Wang Y, Ma X, Wang Y, et al. Comparison of different scoring systems in the assessment of estrogen receptor status for predicting prognosis in endometrial cancer. Int J Gynecol Pathol 2019; 38 (2): 111– doi: 10.1097/PGP.0000000000000490.
  41. Angus L, Beije N, Jager A, et al. ESR1 mutations: Moving towards guiding treatment decisionmaking in metastatic breast cancer patients. Cancer Treat Rev 2017; 52: 33–40. doi: 10.1016/j.ctrv.2016.11.001.
  42. Yano M, Ito K, Yabuno A, et al. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. Mod Pathol 2019; 32 (7): 1023–31. doi: 10.1038/s41379-019-0220-1.
  43. Zhang XX, Luo JH, Wu LQ. FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Front Genet 2022; 13: 913659. doi: 10.3389/fgene.2022.913659.

No comments » Add comment